Latest Information Update: 06 Oct 2006
At a glance
- Originator Novartis
- Mechanism of Action Metalloprotease inhibitors; Tumour necrosis factor-alpha convertase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Bacterial meningitis
Most Recent Events
- 06 Oct 2006 Discontinued - Preclinical for Bacterial meningitis in Switzerland (unspecified route)
- 27 Sep 2000 Preclinical development for Bacterial meningitis in Switzerland (Unknown route)